REFERENCES
-
1
Grobbee D E, Bots M L.
Statin treatment and progression of atherosclerotic plaque burden.
Drugs.
2003;
63
893-911
-
2
Stefanadis C, Toutouzas K, Vavuranakis M et al..
Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques.
Eur Heart J.
2002;
23
1664-1669
-
3
Crisby M, Nordin-Fredriksson G, Shah P K, Yano J, Zhu J, Nilsson J.
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques-implications for plaque stabilization.
Circulation.
2001;
103
926-933
-
4
Cipollone F, Fazia M, Iezzi A et al..
Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
Circulation.
2003;
107
1479-1485
-
5
Davignon J.
The cardioprotective effects of statins.
Curr Atheroscler Rep.
2004;
6
27-35
-
6
Weitz-Schmidt G.
Statins as anti-inflammatory agents.
Trends Pharmacol Sci.
2002;
23
482-486
-
7
Wan M X, Schramm R, Klintman D, Welzenbach K, Weitz-Schmidt G, Thorlacius H.
A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon.
Br J Pharmacol.
2003;
140
395-401
Jean DavignonO.C. M.D.
Director, Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal (IRCM)
110 Pine Ave. West, Montreal
QC H2W 1R7, Canada
